Actively Recruiting

Age: 18Years - 90Years
All Genders
NCT06798376

Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer

Led by Chinese PLA General Hospital · Updated on 2025-01-29

300

Participants Needed

1

Research Sites

2 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this observational study is to analyze the impact of different durations of neoadjuvant PD-1 inhibitor combined with chemotherapy on tumor regression and safety in patients with advanced gastric cancer. The main questions it aims to answer are: * Does the duration of neoadjuvant treatment influence tumor regression grading (TRG)? * How does treatment duration affect perioperative safety and clinical outcomes? Participants who have previously undergone neoadjuvant PD-1 inhibitor combined with chemotherapy followed by surgery as part of their routine medical care will have their clinical data retrospectively reviewed and analyzed.

CONDITIONS

Official Title

Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer

Who Can Participate

Age: 18Years - 90Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Non-bedridden patients aged 18-90 years
  • Histologically confirmed gastric or gastroesophageal junction adenocarcinoma by biopsy
  • Evaluated as resectable advanced gastric cancer via CT, MRI, or laparoscopic exploration
  • No prior anti-tumor treatments such as chemotherapy, radiotherapy, or immunotherapy
  • No history of other malignancies within the past 5 years
  • Received at least one cycle of PD-1 inhibitor combined with chemotherapy preoperatively
  • Underwent radical gastrectomy after neoadjuvant therapy
  • No severe underlying diseases
Not Eligible

You will not qualify if you...

  • Incomplete or inaccessible clinical and pathological data
  • Postoperative pathology confirming non-gastric or non-gastroesophageal junction adenocarcinoma
  • Distant metastases present prior to treatment
  • Concurrent diagnosis of other malignancies

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Chinese PLA General Hospital

Beijing, China, 100853

Actively Recruiting

Loading map...

Research Team

X

Xinxin Wang

CONTACT

S

Shuo Li

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here